Wu Ting, Wang Qun, Ding Ming, Zhu Xiaoli, Wu Ying
Clin Lab. 2020 Nov 1;66(11). doi: 10.7754/Clin.Lab.2020.200310.
Although increasing evidence has shown that long non-coding RNA BLACAT1 could be aberrantly expressed and used as a prognostic marker in various cancers, the results remain inconclusive. In this study, we sought to summarize the relationship between BLACAT1 (bladder cancer associated transcript 1) and relevant clinical outcomes.
Eligible studies were retrieved from the online databases PubMed and Web of Science. A meta-analysis was performed using Stata 12.0 software. The Cancer Genome Atlas (TCGA) dataset was further used to verify the results.
A total of sixteen studies were included to evaluate the association of BLACAT1 with overall survival or clinicopathological features by pooled hazard ratio (HR) or odds ratio (OR) in cancer. In the pooled analyses stratified by clinicopathological features, BLACAT1 expressions were closely correlated with lymph node metastasis (OR = 2.52, 95% CI: 1.86 - 3.40, p = 0.000), histological differentiation (OR = 1.98, 95% CI 1.25 - 3.13, p = 0.004), and tumor stage (OR = 1.89, 1.23 - 2.91, p = 0.004), but not to tumor size (OR = 1.91, 95% CI 0.96 - 3.80, p = 0.064) or distant metastasis (OR = 3.76, 95% CI: 0.90 - 15.71, p = 0.07) in cancer. Our results manifested that elevated BLACAT1 expression was markedly associated with poor overall survival (HR = 1.62, 95% CI: 1.41 - 1.84, p = 0.000) and PFS (HR = 2.10, 95% CI: 1.28 - 2.93, p < 0.001) among twelve types of solid cancers. Subgroup analysis demonstrated a significant association between high BLACAT1 expression and shorter OS in the lung cancer (HR = 2.03, 95% CI: 1.66 - 2.40, p = 0.000), colorectal cancer (HR = 1.47, 95% CI: 1.3 - 1.64, p = 0.000). Using Cox multivariate analyses, BLACAT1 expression was found to be an independent prognostic marker for OS in cancer (HR = 1.83, 95% CI: 1.37 - 2.30). TCGA dataset also confirmed that the upregulated BLACAT1 expression was significantly correlated with poor prognosis in cancer.
Increased BLACAT1 expression was associated with more advanced clinicopathological features and may serve as poor prognosis in various cancers.
尽管越来越多的证据表明长链非编码RNA BLACAT1在多种癌症中可能异常表达并可作为预后标志物,但结果仍无定论。在本研究中,我们试图总结BLACAT1(膀胱癌相关转录本1)与相关临床结局之间的关系。
从在线数据库PubMed和Web of Science中检索符合条件的研究。使用Stata 12.0软件进行荟萃分析。进一步使用癌症基因组图谱(TCGA)数据集验证结果。
共纳入16项研究,通过合并风险比(HR)或癌症中的比值比(OR)评估BLACAT1与总生存期或临床病理特征的关联。在按临床病理特征分层的合并分析中,BLACAT1表达与淋巴结转移(OR = 2.52,95% CI:1.86 - 3.40,p = 0.000)、组织学分化(OR = 1.98,95% CI 1.25 - 3.13,p = 0.004)和肿瘤分期(OR = 1.89,1.23 - 2.91,p = 0.004)密切相关,但与癌症中的肿瘤大小(OR = 1.91,95% CI 0.96 - 3.80,p = 0.064)或远处转移(OR = 3.76,95% CI:0.90 - 15.71,p = 0.07)无关。我们的结果表明,在12种实体癌中,BLACAT1表达升高与较差的总生存期(HR = 1.62,95% CI:1.41 - 1.84,p = 0.000)和无进展生存期(HR = 2.10,95% CI:1.28 - 2.93,p < 0.001)显著相关。亚组分析表明,在肺癌(HR = 2.03,95% CI:1.66 - 2.40,p = 0.000)、结直肠癌(HR = 1.47,95% CI:1.3 - 1.64,p = 0.000)中,高BLACAT1表达与较短的总生存期之间存在显著关联。使用Cox多变量分析,发现BLACAT1表达是癌症总生存期的独立预后标志物(HR = 1.83,95% CI:1.37 - 2.30)。TCGA数据集也证实,BLACAT1表达上调与癌症预后不良显著相关。
BLACAT1表达增加与更晚期的临床病理特征相关,可能是多种癌症预后不良的标志。